Back then its possible they were not doing 50/50 maybe a reason for that qtr low as 50/50 not in effect. There was an announcement mid year 2019 about both organisations revenues. We know revenue is split, we don't know when this started to be split. There accounts should explain what there operating expenses are. Wages is easy, but so much is lumped into operating without explanation, the commissions, have to be in this as there not anywhere else in there books.
Outside this, revenue was flat. Less than q4 2018 and just 7% up on q3 2019. Remember q4 is the strong qtr. I think this is what the market looked at. With mid year growth, they should not have had lower q4 2019 than q4 2018 esp with a large growth in etas, that means advantage didn't to do well. Imagine no etas growth.
Definatelly not effected by chat hear, as we only a few, the broad market disapproved.
It's been oversold I feel. I'm down 90k. It's paper profit gone. So good value at present. I think investors will be bit weary into next qtr as the price I feel was up over 2. 5c on anticipation of a cracker quarter.
- Forums
- ASX - By Stock
- SCL
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-49
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SCL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online